AU9152891A - A method of inhibiting endotoxin induced effects - Google Patents

A method of inhibiting endotoxin induced effects

Info

Publication number
AU9152891A
AU9152891A AU91528/91A AU9152891A AU9152891A AU 9152891 A AU9152891 A AU 9152891A AU 91528/91 A AU91528/91 A AU 91528/91A AU 9152891 A AU9152891 A AU 9152891A AU 9152891 A AU9152891 A AU 9152891A
Authority
AU
Australia
Prior art keywords
formula
agmatin
compound according
immobilized
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU91528/91A
Other languages
English (en)
Inventor
Christer Grimfors
Ellinor Lampen
Svante Lindgren
Goran Sandberg
Raymond Wahlen
Bjorn Westberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Publication of AU9152891A publication Critical patent/AU9152891A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU91528/91A 1991-01-09 1991-12-20 A method of inhibiting endotoxin induced effects Withdrawn AU9152891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
SE9100059 1991-01-09

Publications (1)

Publication Number Publication Date
AU9152891A true AU9152891A (en) 1992-08-17

Family

ID=20381566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91528/91A Withdrawn AU9152891A (en) 1991-01-09 1991-12-20 A method of inhibiting endotoxin induced effects

Country Status (11)

Country Link
EP (4) EP0719550B1 (enExample)
JP (1) JP3200604B2 (enExample)
AT (2) ATE204753T1 (enExample)
AU (1) AU9152891A (enExample)
DE (2) DE69223426T2 (enExample)
DK (2) DK0719550T3 (enExample)
ES (2) ES2163543T3 (enExample)
GR (1) GR3025573T3 (enExample)
PT (1) PT715849E (enExample)
SE (1) SE468881B (enExample)
WO (1) WO1992011847A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
EP0738146B1 (en) * 1994-01-11 2003-05-02 N.V. Nutricia Method of treating disorders of the animal or human body by administering amino acids
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
ATE279919T1 (de) * 1997-08-15 2004-11-15 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
EP2386861A3 (en) 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US9375499B2 (en) 2006-07-14 2016-06-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
EP0566644A1 (en) 1993-10-27
EP0719550A3 (enExample) 1996-07-24
DE69223426D1 (de) 1998-01-15
ES2109338T3 (es) 1998-01-16
SE468881B (sv) 1993-04-05
GR3025573T3 (en) 1998-03-31
ATE157866T1 (de) 1997-09-15
EP0719550A2 (en) 1996-07-03
DK0719550T3 (da) 2001-12-10
EP0566644B1 (en) 1997-09-10
JPH06504058A (ja) 1994-05-12
SE9100059L (sv) 1992-07-10
DE69223426T2 (de) 1998-03-12
EP0715849B1 (en) 2001-07-25
ES2163543T3 (es) 2002-02-01
PT715849E (pt) 2002-01-30
JP3200604B2 (ja) 2001-08-20
EP0494848A1 (en) 1992-07-15
ATE204753T1 (de) 2001-09-15
EP0715849A1 (en) 1996-06-12
EP0719550B1 (en) 2001-08-29
DK0566644T3 (da) 1998-04-27
SE9100059D0 (sv) 1991-01-09
DE69132710T2 (de) 2002-04-18
EP0494848B1 (en) 1997-03-26
DE69132710D1 (de) 2001-10-04
WO1992011847A1 (en) 1992-07-23

Similar Documents

Publication Publication Date Title
EP0494848A1 (en) Method of removing endotoxins
JP2929516B2 (ja) 水性液体から腫瘍壊死因子または／およびリポ多糖を定量的、選択的に除去するかまたは／および調製的に製取する方法、液体から腫瘍壊死因子および／またはリポ多糖を体外除去する装置、装置ユニットおよび吸着材料
JPS62242628A (ja) プロテインａ−シリカ免疫吸着剤及びその製造方法
JPH0567305B2 (enExample)
NL7905220A (nl) Antitrombinepreparaat en werkwijze ter bereiding ervan.
JPS5944320A (ja) Ｃ１不活性化剤の調製方法
EP1226829B1 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
JPH08299436A (ja) 全血及び／又は血漿から腫瘍壊死因子α及び細菌性リポ多糖類を同時体外除去する方法及び装置
BYSANI et al. Detoxification of plasma containing lipopolysaccharide by adsorption
JPS63165328A (ja) 組織タンパクｐｐ４含有医薬
JP2004516888A (ja) 炭水化物含有溶液の解毒方法
Malchesky et al. Extracorporeal techniques of endotoxin removal: a review of the art and science
JP4366081B2 (ja) 高度に精製されたアンチエンドトキシン化合物
US20070287661A1 (en) Compositions and methods for prevention or treatment of thrombocytopenia and methods for manufacturing said compositions
NL8006706A (nl) Farmaceutische preparaten van therapeutische waarde voor het behandelen van acute longoedemen, sommige shocktoestanden en hyperfibrinolyse.
FI62103C (fi) Foerfarande foer framstaellning av heparin med hoeg specifik aktivitet
AU2005265960A1 (en) Process for improvement of virus-safe biological fluids
JPS6159610B2 (enExample)
JPH029600B2 (enExample)
CA1257203A (en) Dialysis with monophosphoryl lipid a
AU717541B2 (en) Inactivation of viruses by incubation with caprylate
Umeda et al. Adsorption and removal of endotoxin by polymyxin-Sepharose, its properties and applications
EP1551464A1 (en) New composition use and method
JPS5841823A (ja) 尿の保存方法
DE10131404A1 (de) Stabilisierte Flüssigzubereitung für den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms